Ab-NAT-. The aviremic HCV kidneys were recovered from donors who were significantly younger, more likely to be white, and less likely to have hypertension and diabetes. The majority of the recipients of the aviremic HCV kidneys when compared to matched controls were HCV positive: 90.2% vs 4.3%. The recipients were significantly older, were on dialysis for a shorter time, and were transplanted sooner. The graft survival of aviremic HCV kidneys was similar (P < .08). If the HCV status of the aviremic kidneys was assumed to be negative, 122 more kidneys could have been allocated to patients with estimated posttransplant survival <20. Seven kidneys would no longer have Kidney Donor Profile Index >85%. Further policies might consider these findings to appropriately allocate these kidneys.
K E Y W O R D S
clinical research/practice, graft survival, infection and infectious agents-viral: hepatitis C, kidney transplantation/nephrology selection. The KDRI of each kidney is then mapped into a Kidney Donor Profile Index (KDPI) scale from 1 (Best) to 100 (Worst). The lower the KDPI is, the better the quality of the kidney. As a result of the new kidney allocation system (KAS) introduced in 2014, to promote better longevity matching, kidneys of better quality from donors with KDPI <20% are offered to the healthiest candidates with Estimated Posttransplant Survival (EPTS) score <20. KDRI is based on 10 donor factors including HCV status from serological or nucleic acid amplification testing (NAT). Based on the analysis of the national database of 69 440 deceased donor adult transplants, donor HCV infection was found to be independently associated with graft failure or death, increasing the hazard ratio for graft failure by 1.27, and the KDPI by approximately 20%. 4 In 2015, all Organ Procurement Organizations were mandated to perform and report HCV NAT results, in addition to HCV antibody status for all organ donors. As a result, it is now possible to distinguish various risks associated with HCV-positive donors, including that HCV antibody positive and nucleic acid testing negative (Ab+ NAT-) donors likely pose a minimal risk of viral transmission to the recipient. 5 Therefore, we hypothesize that the quality and outcomes of kidneys recovered from the HCV Ab+NAT-donors are superior to the quality and outcomes of the kidneys from the donors who are non-HCV antibody negative and nucleic acid testing negative (Ab-NAT-) with the same KDRI calculated by the currently used KDRI scoring system. The present study was undertaken to demonstrate that if the HCV status in the KDRI calculation formula was considered negative instead of positive as it currently stands for HCV Ab+NAT-donor kidneys, the graft and patient survivals of the HCV aviremic kidneys would be similar to HCV-negative kidneys with the same KDRI. We also hypothesized that more HCV aviremic kidneys would be allocated to patients with longer survival, ie with EPTS <20%, and fewer kidneys would be considered extended criteria, ie KDPI >85%.
| ME THODS
We conducted a retrospective matched case-control analysis of deceased donor kidney-alone transplants from the UNOS Standard This group also had 13 missing values for cold ischemia time, and these values were imputed using linear regression by distance from the procuring center to the transplant center. Delayed graft function (DGF) in the transplanted grafts had <0.06% missing data and the majority of the immediate graft function was imputed for the missing data. Acute rejection episodes in the first month following transplant had <0.007% missing data and the majority of no rejection was imputed for the missing data. Sensitivity analysis revealed that these imputations made no difference to the final results.
Three separate retrospective matched case-control datasets were constructed by random matching of observations from the larger set that had the characteristics for matching of the smaller cohort. Statistical power analysis revealed that an 11-to-1 ratio of controls to cases was required to detect a 5% difference in allograft survival. One dataset was created by matching the standard (assigned) KDRI scoring system as HCV status positive for the Ab+NAT-and negative for the Ab-NAT-group. A second dataset was created by matching the standard KDRI and EPTS score of the recipients. A third dataset was created by matching the modified (recalculated) KDRI for the HCV Ab+NAT-recipients based on the Rao et al scoring system, assuming HCV status to be negative and EPTS score of the recipients. 6 Primary end-points were graft and patient survival in the 3 different case-controlled datasets.
| Statistical analysis
Analyses were conducted using JMP Pro 13. dataset were chosen to demonstrate statistical significance at 5% level of significance (P value of <.05) with a power of 80%. Matching for the case-controlled dataset was performed on the variables within 0.1 for KDRI and within 10% by EPTS when both variables were used.
UNOS characteristics of HCV negative and aviremic HCV positive groups were compared using the χ 2 or Fisher exact test for categorical values and the Student t test for continuous variables. Survival rates were presented in Kaplan-Meier curves. The log-rank test was used to calculate the statistical difference between the 2 groups. (P = .001) and trended to have more peripheral vascular disease.
| RE SULTS

| HCV aviremic vs non-HCV kidney donors
| HCV aviremic vs non-HCV kidney recipients
They were more likely to have had a previous transplant. They spent a significantly shorter time on dialysis (1175 ± 886 days vs 1949 ± 1311 days) (P < .0001) and waited for a kidney transplant for a significantly shorter period of time (432 ± 556 days vs 938.6 ± 884 days) (P < .0001) ( Table 2 ).
| Transplantation of HCV Ab+NAT-kidneys by transplant center's experience and size
The match control for KDRI group revealed the use of HCV Ab+NAT-kidneys ( Figure 1 ). 
| Patient and graft survival
The KDRI of the HCV aviremic kidneys was calculated based on the Rao et al scoring system and was considered standard. The KDRI of the HCV aviremic kidneys was then recalculated by assuming HCV status to be negative and thus was considered modified KDRI.
When matched by the standard KDRI calculated by the Rao et al scoring formula and the recipient EPTS score, the 1-year graft survival of HCV aviremic kidneys was 96 ± 0.02% compared to non-HCV kidneys (92.2 ± 0.1%), and trended toward better survival (P = .08) ( Figure 3A) . No difference in 1-year patient survival was noted when 2 groups were compared ( Figure 3B ). The incidence of DGF was 19% in the HCV aviremic kidney recipients while it was 33.9% DGF (P < .0001) in the non-HCV kidney recipients. The Ab+ NAT-group had 3 (1.5%) acute rejection episodes compared to the Ab-NAT-group with 40 (1.8%) acute rejection episodes (P = .74).
When the modified KDRI of the aviremic HCV kidneys was matched by the KDRI and EPTS score of the recipients of the non-HCV kidneys, the 1-year graft survival was 96 ± 0.02% vs 96 ± 0.005%, respectively. The graft and patient survival rates were not significantly different ( Figure 4 ). The incidence of DGF was 19% in the HCV aviremic kidney recipients, while it was 25.7% (P = .02) in the non-HCV kidney recipients. The Ab-NAT-group had 36 (1.6%) acute rejection episodes compared to 3 (1.5%) in the Ab+NAT-group (P = .35).
| Distribution of HCV aviremic donors based on KDPI
The KDRI of each kidney was mapped into a KDPI scale from 1 (Best)
to 100 (Worst). When standard KDRI was used, none of the HCV 
| D ISCUSS I ON
Nationwide, since 2010, as a result of the opioid epidemic, the number of new HCV infections has tripled. 7 Since 2000, there has been a 200% increase in the rate of overdose deaths involving opioids. 8, 9 As a result, the number of HCV positive donors is increasing as well. 10 Nearly all the recipients of organs from viremic HCV donors become infected with HCV. 11 The remaining HCV This study is unique in that it is the first large study to distinguish among kidney allografts based on HCV Ab and NAT status.
Our analysis has limitations, including the inherent limitations of a large national dataset, including miscoding and the interpretation of prior actions to predict future events. Donor NAT testing result reporting has only recently become required, and the study is based on 1 year of data, and thus the data on long-term patient and graft survival are limited.
In conclusion, the KDRI provides us with a qualitative evaluation of deceased donor quality, 4, 17 but in the case of HCV infection we demonstrated that KDRI underestimates the superior quality and outcomes of the kidney grafts recovered from the HCV aviremic donors. Kidneys from aviremic HCV donors could be safely transplanted into HCV negative recipients achieving a longer survival.
Future policies might consider these findings to appropriately allocate these kidneys in order to potentially likely extend graft survival, provide better longevity matching, and limit the organ discard rate. 
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